With less than one month until the US DSCSA deadline, RAPS member Greg Cathcart says the biggest concern for firms is understanding what is required, and when.
AAPS PharmSci 360 is a new conference this year, created in response to a desire for “fresh science,” specifically with chemical and biomolecular components. So what can you expect?
The pharmaceutical supply services provider Experic has marked its official launch with plans to construct its headquarters at a newly leased Class A research, manufacturing, and packaging facility.
CMO-focused marketing and PR agency, ramarketing, has signed a lease on offices in the rapidly growing pharma and biotech hub of Cambridge, Massachusetts.
in-PharmaTechnologist (IPT) speaks to Ettore Cucchetti (EC), CEO of ACGI, about how the biopharma industry is adapting to the threat of counterfeit medicine and how he expects the industry will adopt further measures beyond those stipulated in the EU...
Tjoapack and Veratrak partnered to establish the use of blockchain technology across the pharmaceutical industry for the first time in a GxP environment.
Fermion Oy has completed construction of its manufacturing plant in Hanko, Finland, where it will make highly potent ingredients for ‘main markets’ and a growing client base in India, says president.
This year’s DIA Global Annual Meeting will focus on the latest global trends and showcase the "diverse group of key individuals driving the life science ecosystem forward," says DIA Americas managing director.
Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.
Significant regulatory changes by the Chinese government will accelerate drug development timelines and positively affect sponsors’ bottom line, says CRO.
Almac Group has expanded its commercial packaging capabilities to meet a “significant increase” in demand for complex kit assembly as biopharma brings more advanced sterile and biological products to the market, says CDMO.
Pharma must brace itself for production scheduling clashes and cost challenges ahead of next year’s Falsified Medicines Directive (FMD) says PharmSource.
Pharma must look outward to innovate and find new areas of growth, as research and development productivity and returns on innovation continue to decline, says industry expert.
At DCAT Week, contract manufacturing and development companies from across the globe shared updates and news – from multi-million dollar investments to new business structures and areas of focus.
Grand River Aseptic Manufacturing has purchased a new lot of land to expand its manufacturing capabilities as growth in the market drives demand, says CEO.
PCI Pharma Services has validated its former Millmount site to help Ireland’s ‘thriving pharma community’ comply with Europe’s Falsified Medicines Directive.
CDMOs continue to take on a larger role supporting sponsors in the pharmaceutical industry, though new technology and changing requirements could shift the models in which they operate.
Grand River Aseptic Manufacturing (GRAM) has purchased a new syringe filler to help meet "the rising demand" for parenteral development and manufacturing services.
Increased enforcement of cGMP on over-the-counter (OTC) drugs is highlighting the grey-area in classification with cosmetic products, a former FDA director says.
With fewer global mid-sized contract research organizations (CRO) through consolidation, some stakeholders are expressing concern that the industry could become a monopoly – “we may be getting there,” one expert said.
CordenPharma has revamped its executive leadership team, Recipharm has named the head of its new global development organization, and several new CEOs have been appointed.
The detection of cracks of the surface of glass vials has prompted a voluntary recall of Labetalol Hydrochloride Injection made at Pfizer’s troubled McPherson, Kansas facility.
Scientist.com is working to implement an improved contractual landscape ahead of GDPR implementation in May, in order to ensure global compliance among sponsors and CROs.
Massachusetts biopharma companies received $2.9bn in venture capital investment in 2016 – and as pressure continues to accelerate the drug development process, manufacturers will continue to turn to CROs and CMOs, says MassBio.
Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.
